We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
RAN is not prognostic in Glioblastoma Multiforme (TCGA)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: 0.98
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
0.42
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
10%
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
9%
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
601.6
Number of samples
141
Samples
Sample
Description
TPM
TCGA-32-5222-01A
66 years, male, white, stage:'--, dead, 585 days
1196.4
TCGA-27-2521-01A
34 years, male, white, stage:'--, dead, 510 days
1131.2
TCGA-06-5416-01A
23 years, female, white, stage:'--, alive, 204 days
1043.1
TCGA-06-5413-01A
67 years, male, white, stage:'--, alive, 268 days
1043.0
TCGA-12-5295-01A
60 years, female, white, stage:'--, dead, 454 days
1007.8
TCGA-28-5208-01A
52 years, male, white, stage:'--, dead, 544 days
950.1
TCGA-02-2483-01A
43 years, male, asian, stage:'--, alive, 466 days
900.2
TCGA-28-5204-01A
72 years, male, white, stage:'--, dead, 454 days
876.1
TCGA-27-2524-01A
56 years, male, white, stage:'--, dead, 231 days
875.4
TCGA-76-4925-01A
76 years, male, white, stage:'--, dead, 146 days
854.9
TCGA-14-1825-01A
70 years, male, white, stage:'--, dead, 232 days
844.6
TCGA-28-5220-01A
67 years, male, white, stage:'--, dead, 388 days
836.6
TCGA-14-0871-01A
74 years, female, white, stage:'--, dead, 880 days
833.5
TCGA-06-0178-01A
38 years, male, white, stage:'--, dead, 2681 days
821.3
TCGA-12-0616-01A
36 years, female, white, stage:'--, dead, 448 days
789.4
TCGA-32-2634-01A
82 years, male, white, stage:'--, alive, 693 days
785.9
TCGA-06-5408-01A
54 years, female, white, stage:'--, dead, 357 days
785.4
TCGA-27-2523-01A
63 years, male, white, stage:'--, dead, 489 days
784.8
TCGA-06-0156-01A
57 years, male, white, stage:'--, dead, 178 days
780.4
TCGA-06-0219-01A
67 years, male, white, stage:'--, dead, 22 days
773.9
TCGA-28-2509-01A
77 years, female, white, stage:'--, alive, 145 days
770.7
TCGA-12-0821-01A
62 years, male, white, stage:'--, dead, 323 days
767.5
TCGA-12-3650-01A
46 years, male, white, stage:'--, dead, 333 days
767.2
TCGA-12-5299-01A
56 years, female, white, stage:'--, dead, 98 days
758.1
TCGA-12-3653-01A
34 years, female, white, stage:'--, dead, 442 days
757.9
TCGA-06-2558-01A
75 years, female, white, stage:'--, dead, 380 days
754.2
TCGA-19-5960-01A
56 years, male, white, stage:'--, dead, 455 days
752.9
TCGA-06-0644-01A
71 years, male, black or african american, stage:'--, dead, 384 days
748.1
TCGA-76-4932-01A
50 years, female, white, stage:'--, dead, 1458 days
724.6
TCGA-12-3652-01A
60 years, male, white, stage:'--, dead, 1062 days
718.4
TCGA-06-0130-01A
54 years, male, white, stage:'--, dead, 394 days
713.8
TCGA-76-4931-01A
70 years, female, white, stage:'--, dead, 279 days
713.6
TCGA-28-5207-01A
71 years, male, white, stage:'--, dead, 343 days
713.2
TCGA-27-1831-01A
66 years, male, white, stage:'--, dead, 505 days
712.3
TCGA-06-0745-01A
59 years, male, white, stage:'--, dead, 239 days
711.5
TCGA-41-5651-01A
59 years, female, black or african american, stage:'--, dead, 460 days
711.1
TCGA-28-5209-01A
66 years, female, white, stage:'--, alive, 442 days
709.3
TCGA-26-5132-01A
74 years, male, white, stage:'--, alive, 286 days
708.8
TCGA-06-5411-01A
51 years, male, white, stage:'--, dead, 254 days
703.2
TCGA-06-5856-01A
58 years, male, white, stage:'--, dead, 114 days
695.3
TCGA-06-0686-01A
53 years, male, white, stage:'--, dead, 432 days
693.7
TCGA-14-0817-01A
69 years, female, white, stage:'--, dead, 164 days
690.3
TCGA-15-0742-01A
65 years, male, white, stage:'--, dead, 419 days
683.1
TCGA-06-0174-01A
54 years, male, white, stage:'--, dead, 98 days
677.8
TCGA-02-2485-01A
53 years, male, black or african american, stage:'--, alive, 470 days
677.1
TCGA-06-0238-01A
46 years, male, white, stage:'--, dead, 405 days
672.9
TCGA-06-5858-01A
45 years, female, white, stage:'--, alive, 187 days
666.1
TCGA-14-2554-01A
52 years, female, white, stage:'--, dead, 532 days
658.4
TCGA-19-4065-01A
36 years, male, white, stage:'--, alive, 214 days
657.3
TCGA-32-2616-01A
48 years, female, white, stage:'--, dead, 224 days
653.1
TCGA-06-2567-01A
65 years, male, white, stage:'--, dead, 133 days
638.4
TCGA-26-5133-01A
59 years, male, white, stage:'--, alive, 452 days
637.8
TCGA-06-5417-01A
45 years, female, white, stage:'--, alive, 155 days
619.4
TCGA-06-5412-01A
78 years, female, white, stage:'--, dead, 138 days
615.0
TCGA-06-2559-01A
83 years, male, white, stage:'--, dead, 150 days
611.2
TCGA-76-4927-01A
58 years, male, white, stage:'--, dead, 535 days
610.1
TCGA-14-1034-01A
60 years, female, stage:'--, dead, 485 days
609.1
TCGA-28-5216-01A
52 years, male, white, stage:'--, alive, 415 days
605.1
TCGA-14-0787-01A
69 years, male, asian, stage:'--, dead, 68 days
604.1
TCGA-28-2514-01A
45 years, male, asian, stage:'--, alive, 160 days
602.8
TCGA-41-2572-01A
67 years, male, white, stage:'--, dead, 406 days
602.7
TCGA-06-5859-01A
63 years, male, white, stage:'--, alive, 139 days
598.2
TCGA-76-4929-01A
76 years, female, white, stage:'--, dead, 111 days
597.2
TCGA-28-5215-01A
62 years, female, white, stage:'--, dead, 335 days
595.0
TCGA-06-2563-01A
72 years, female, white, stage:'--, alive, 932 days
587.8
TCGA-06-0125-01A
63 years, female, white, stage:'--, dead, 1448 days
586.9
TCGA-02-2486-01A
64 years, male, white, stage:'--, dead, 618 days
581.0
TCGA-28-5218-01A
63 years, male, white, stage:'--, dead, 157 days
580.9
TCGA-06-2570-01A
21 years, female, white, stage:'--, alive, 958 days
576.2
TCGA-06-0129-01A
30 years, male, asian, stage:'--, dead, 1024 days
575.0
TCGA-06-2561-01A
53 years, female, white, stage:'--, dead, 537 days
574.2
TCGA-06-5418-01A
75 years, female, white, stage:'--, dead, 83 days
568.1
TCGA-08-0386-01A
74 years, male, white, stage:'--, dead, 548 days
566.6
TCGA-27-2528-01A
62 years, male, white, stage:'--, dead, 480 days
564.2
TCGA-06-5414-01A
61 years, male, white, stage:'--, alive, 273 days
562.1
TCGA-02-0055-01A
62 years, female, white, stage:'--, dead, 76 days
560.7
TCGA-06-0210-01A
72 years, female, white, stage:'--, dead, 225 days
558.1
TCGA-28-1753-01A
53 years, male, white, stage:'--, alive, 37 days
557.6
TCGA-06-0211-01A
47 years, male, white, stage:'--, dead, 360 days
557.4
TCGA-06-2569-01A
24 years, female, black or african american, stage:'--, alive, 13 days
557.0
TCGA-19-2619-01A
55 years, female, black or african american, stage:'--, alive, 294 days
553.2
TCGA-12-0618-01A
49 years, male, white, stage:'--, dead, 395 days
551.5
TCGA-06-2562-01A
81 years, male, white, stage:'--, dead, 382 days
549.9
TCGA-32-2615-01A
62 years, male, white, stage:'--, dead, 485 days
545.2
TCGA-06-0139-01A
40 years, male, white, stage:'--, dead, 362 days
544.3
TCGA-06-0157-01A
63 years, female, white, stage:'--, dead, 97 days
540.9
TCGA-27-2526-01A
79 years, female, white, stage:'--, dead, 87 days
536.2
TCGA-14-1823-01A
58 years, female, white, stage:'--, dead, 543 days
533.3
TCGA-06-0168-01A
59 years, female, white, stage:'--, dead, 598 days
532.1
TCGA-06-5410-01A
72 years, female, white, stage:'--, dead, 108 days
531.2
TCGA-26-5139-01A
65 years, female, white, stage:'--, alive, 48 days
528.6
TCGA-06-0744-01A
66 years, male, white, stage:'--, dead, 1426 days
528.4
TCGA-06-0882-01A
30 years, male, white, stage:'--, dead, 632 days
524.9
TCGA-26-5135-01A
72 years, female, white, stage:'--, dead, 270 days
523.2
TCGA-32-2632-01A
80 years, male, white, stage:'--, dead, 269 days
520.4
TCGA-19-2629-01A
60 years, male, white, stage:'--, dead, 737 days
518.3
TCGA-32-1970-01A
59 years, male, white, stage:'--, dead, 468 days
516.9
TCGA-06-0646-01A
60 years, male, white, stage:'--, dead, 175 days
516.4
TCGA-06-0878-01A
74 years, male, white, stage:'--, alive, 218 days
510.0
TCGA-06-2564-01A
50 years, male, white, stage:'--, alive, 181 days
508.6
TCGA-06-0138-01A
43 years, male, white, stage:'--, dead, 737 days
502.0
TCGA-06-1804-01A
81 years, female, white, stage:'--, dead, 414 days
490.5
TCGA-06-0190-01A
62 years, male, white, stage:'--, dead, 317 days
489.1
TCGA-06-2565-01A
59 years, male, asian, stage:'--, dead, 506 days
480.9
TCGA-06-2557-01A
76 years, male, black or african american, stage:'--, dead, 33 days
477.7
TCGA-15-1444-01A
21 years, male, white, stage:'--, dead, 1537 days
477.0
TCGA-02-0047-01A
78 years, male, white, stage:'--, dead, 448 days
473.8
TCGA-27-1830-01A
57 years, male, white, stage:'--, dead, 154 days
471.4
TCGA-32-1980-01A
72 years, male, white, stage:'--, dead, 36 days
471.4
TCGA-28-2513-01A
69 years, female, white, stage:'--, alive, 222 days
468.0
TCGA-06-0645-01A
55 years, female, white, stage:'--, dead, 175 days
467.9
TCGA-32-1982-01A
76 years, female, white, stage:'--, dead, 142 days
467.4
TCGA-27-1837-01A
36 years, male, white, stage:'--, dead, 427 days
464.3
TCGA-06-0141-01A
62 years, male, white, stage:'--, dead, 313 days
459.7
TCGA-19-1390-01A
63 years, female, white, stage:'--, dead, 772 days
454.7
TCGA-06-0132-01A
49 years, male, white, stage:'--, dead, 771 days
453.6
TCGA-19-2624-01A
51 years, male, white, stage:'--, dead, 5 days
452.8
TCGA-41-3915-01A
48 years, male, white, stage:'--, dead, 360 days
449.1
TCGA-27-1832-01A
59 years, female, white, stage:'--, dead, 300 days
447.1
TCGA-41-2571-01A
89 years, male, white, stage:'--, dead, 26 days
446.5
TCGA-19-2625-01A
76 years, female, white, stage:'--, dead, 124 days
444.4
TCGA-14-1829-01A
57 years, male, black or african american, stage:'--, alive, 218 days
443.1
TCGA-06-0158-01A
73 years, male, white, stage:'--, dead, 329 days
426.1
TCGA-32-2638-01A
67 years, male, white, stage:'--, dead, 766 days
425.4
TCGA-06-0749-01A
50 years, male, black or african american, stage:'--, dead, 82 days
425.3
TCGA-41-4097-01A
63 years, female, white, stage:'--, dead, 6 days
424.6
TCGA-12-0619-01A
60 years, male, white, stage:'--, dead, 1062 days
419.2
TCGA-32-4213-01A
47 years, female, white, stage:'--, alive, 604 days
419.0
TCGA-27-2519-01A
48 years, male, white, stage:'--, dead, 550 days
418.6
TCGA-06-0747-01A
53 years, male, white, stage:'--, dead, 82 days
407.0
TCGA-27-1834-01A
56 years, male, white, stage:'--, dead, 1233 days
406.5
TCGA-06-0750-01A
43 years, male, white, stage:'--, dead, 28 days
404.1
TCGA-14-0789-01A
54 years, male, white, stage:'--, dead, 342 days
391.6
TCGA-06-0743-01A
69 years, male, white, stage:'--, dead, 803 days
389.8
TCGA-16-0846-01A
85 years, male, white, stage:'--, dead, 119 days
382.5
TCGA-19-2620-01A
70 years, male, white, stage:'--, dead, 148 days
324.1
TCGA-06-0184-01A
63 years, male, white, stage:'--, dead, 2126 days
315.9
TCGA-27-1835-01A
53 years, female, white, stage:'--, dead, 648 days
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
RAN is not prognostic in Glioblastoma Multiforme (validation)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: 0.99
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
0.13
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
42%
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
24%
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
48.5
Number of samples
58
Samples
Sample
Description
TPM
AK156
N, NA, stage:NA, dead, 330 days
96.8
AK043
N, NA, stage:NA, alive, 660 days
71.2
AK124
N, NA, stage:NA, alive, 1920 days
68.9
AK142
N, NA, stage:NA, alive, 90 days
67.1
AK199
N, NA, stage:NA, alive, 1860 days
66.2
AK236
N, NA, stage:NA, dead, 360 days
63.7
AK173
N, NA, stage:NA, dead, 180 days
62.4
AK133
N, NA, stage:NA, dead, 360 days
61.6
AK231
N, NA, stage:NA, dead, 240 days
60.9
AK074
N, NA, stage:NA, alive, 300 days
59.1
AK002
N, NA, stage:NA, dead, 570 days
59.0
AK165
N, NA, stage:NA, alive, 360 days
56.9
AK068
N, NA, stage:NA, alive, 360 days
56.2
AK051
N, NA, stage:NA, dead, 360 days
56.0
AK185
N, NA, stage:NA, alive, 330 days
55.9
AK183
N, NA, stage:NA, alive, 360 days
55.5
AK081
N, NA, stage:NA, dead, 180 days
55.2
AK153
N, NA, stage:NA, dead, 240 days
53.5
AK072
N, NA, stage:NA, dead, 150 days
53.5
AK227
N, NA, stage:NA, alive, 300 days
52.3
AK098
N, NA, stage:NA, dead, 660 days
52.0
AK071
N, NA, stage:NA, dead, 540 days
51.5
AK123
N, NA, stage:NA, dead, 180 days
51.1
AK216
N, NA, stage:NA, dead, 360 days
50.9
AK158
N, NA, stage:NA, dead, 360 days
49.7
AK195
N, NA, stage:NA, dead, 390 days
47.7
AK053
N, NA, stage:NA, dead, 300 days
47.0
AK117
N, NA, stage:NA, dead, 210 days
47.0
AK188
N, NA, stage:NA, alive, 420 days
46.4
AK213
N, NA, stage:NA, alive, 2010 days
45.9
AK003
N, NA, stage:NA, dead, 600 days
45.8
AK149
N, NA, stage:NA, dead, 420 days
45.5
AK035
N, NA, stage:NA, dead, 210 days
44.8
AK079
N, NA, stage:NA, dead, 210 days
44.6
AK055
N, NA, stage:NA, dead, 240 days
44.0
AK100
N, NA, stage:NA, alive, 960 days
43.9
AK099
N, NA, stage:NA, dead, 420 days
43.2
AK089
N, NA, stage:NA, dead, 330 days
43.2
AK066
N, NA, stage:NA, alive, 960 days
43.1
AK085
N, NA, stage:NA, alive, 660 days
43.1
AK134
N, NA, stage:NA, dead, 360 days
42.4
AK218
N, NA, stage:NA, dead, 180 days
41.6
AK178
N, NA, stage:NA, dead, 240 days
40.9
AK076
N, NA, stage:NA, alive, 660 days
40.6
AK139
N, NA, stage:NA, dead, 270 days
40.2
AK030
N, NA, stage:NA, dead, 120 days
38.7
AK041
N, NA, stage:NA, alive, 810 days
38.4
AK049
N, NA, stage:NA, dead, 180 days
38.1
AK088
N, NA, stage:NA, dead, 360 days
38.1
AK006
N, NA, stage:NA, dead, 360 days
37.5
AK015
N, NA, stage:NA, alive, 720 days
37.3
AK103
N, NA, stage:NA, alive, 1320 days
36.8
AK226
N, NA, stage:NA, dead, 360 days
36.3
AK167
N, NA, stage:NA, dead, 180 days
34.5
AK205
N, NA, stage:NA, dead, 120 days
30.0
AK091
N, NA, stage:NA, dead, 210 days
29.6
AK102
N, NA, stage:NA, alive, 1740 days
27.3
AK005
N, NA, stage:NA, dead, 240 days
24.6
Show allShow less
GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)
Number of samples
110
Samples
Sample ID
Sample type
nRPX
CPT0217000004
Tumor
1.2
CPT0206230003
Tumor
0.9
CPT0189460003
Tumor
0.8
CPT0206110003
Tumor
0.7
CPT0162100003
Tumor
0.6
CPT0087730003
Tumor
0.6
CPT0205570003
Tumor
0.6
CPT0125570003
Tumor
0.6
CPT0189650004
Tumor
0.6
CPT0219080004
Tumor
0.6
CPT0162020003
Tumor
0.5
CPT0221180003
Tumor
0.5
CPT0087570003
Tumor
0.5
CPT0168380003
Tumor
0.5
CPT0078580003
Tumor
0.4
CPT0087950003
Tumor
0.4
CPT0205780003
Tumor
0.4
CPT0206560003
Tumor
0.4
CPT0206780003
Tumor
0.4
CPT0175060003
Tumor
0.3
CPT0064650003
Tumor
0.3
CPT0205450004
Tumor
0.3
CPT0206880003
Tumor
0.3
CPT0218770003
Tumor
0.3
CPT0093360003
Tumor
0.2
CPT0186100003
Tumor
0.2
CPT0228220003
Tumor
0.2
CPT0064890003
Tumor
0.2
CPT0071100003
Tumor
0.2
CPT0196850003
Tumor
0.2
CPT0167530003
Tumor
0.2
CPT0189850004
Tumor
0.1
CPT0093590003
Tumor
0.1
CPT0127420003
Tumor
0.1
CPT0204420003
Normal
0.1
CPT0189570004
Tumor
0.1
CPT0093550003
Tumor
0.1
CPT0002410011
Tumor
0.1
CPT0206450003
Tumor
0.1
CPT0217060003
Tumor
0.1
CPT0217710008
Tumor
0.1
CPT0217100003
Tumor
0.1
CPT0089150003
Tumor
0.1
CPT0216920008
Tumor
0.1
CPT0182500003
Tumor
0.1
CPT0204390003
Normal
0.0
CPT0123530003
Tumor
0.0
CPT0208980003
Tumor
0.0
CPT0092440003
Tumor
0.0
CPT0204400003
Normal
0.0
CPT0217880003
Tumor
0.0
CPT0168590003
Tumor
0.0
CPT0204410003
Normal
0.0
CPT0204350003
Normal
0.0
CPT0218690004
Tumor
0.0
CPT0182550003
Tumor
0.0
CPT0167640003
Tumor
0.0
CPT0127480003
Tumor
0.0
CPT0093510003
Tumor
-0.1
CPT0204360003
Normal
-0.1
CPT0204330003
Normal
-0.1
CPT0087680003
Tumor
-0.1
CPT0204340003
Normal
-0.1
CPT0201710003
Tumor
-0.1
CPT0199770003
Tumor
-0.1
CPT0217190003
Tumor
-0.1
CPT0218670003
Tumor
-0.1
CPT0125220003
Tumor
-0.1
CPT0225760003
Tumor
-0.1
CPT0168830003
Tumor
-0.1
CPT0190360004
Tumor
-0.1
CPT0204380003
Normal
-0.1
CPT0206000004
Tumor
-0.1
CPT0204370003
Normal
-0.1
CPT0079790003
Tumor
-0.1
CPT0205890003
Tumor
-0.1
CPT0207090003
Tumor
-0.2
CPT0167970003
Tumor
-0.2
CPT0104220003
Tumor
-0.2
CPT0125510003
Tumor
-0.2
CPT0104330003
Tumor
-0.2
CPT0189750004
Tumor
-0.2
CPT0218890004
Tumor
-0.2
CPT0189250003
Tumor
-0.2
CPT0093450003
Tumor
-0.2
CPT0224390004
Tumor
-0.2
CPT0205670004
Tumor
-0.2
CPT0224540004
Tumor
-0.2
CPT0161730003
Tumor
-0.2
CPT0224600003
Tumor
-0.2
CPT0162140003
Tumor
-0.2
CPT0190240004
Tumor
-0.2
CPT0217430008
Tumor
-0.3
CPT0168480003
Tumor
-0.3
CPT0206330003
Tumor
-0.3
CPT0206670004
Tumor
-0.3
CPT0168270003
Tumor
-0.3
CPT0218830004
Tumor
-0.3
CPT0225730003
Tumor
-0.3
CPT0224330003
Tumor
-0.3
CPT0168080003
Tumor
-0.3
CPT0218330004
Tumor
-0.3
CPT0209440003
Tumor
-0.3
CPT0168720003
Tumor
-0.4
CPT0182580003
Tumor
-0.4
CPT0207030003
Tumor
-0.4
CPT0167860004
Tumor
-0.5
CPT0167750004
Tumor
-0.5
CPT0218960004
Tumor
-0.5
CPT0171580008
Tumor
-0.6
Show allShow less
GLIOMA - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.